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Physical exercise is increasingly recognized as a valuable treatment strategy in managing
prostate cancer, not only enhancing supportive care but potentially influencing disease
outcomes. However, there are limited studies investigating mechanisms of the tumor-
suppressive effect of exercise. Recently, extracellular vesicles (EVs) have been recognized
as a therapeutic target for cancer as tumor-derived EVs have the potential to promote
metastatic capacity by transferring oncogenic proteins, integrins, and microRNAs to other
cells and EVs are also involved in developing drug resistance. Skeletal muscle has been
identified as an endocrine organ, releasing EVs into the circulation, and levels of EV-
containing factors have been shown to increase in response to exercise. Moreover,
preclinical studies have demonstrated the tumor-suppressive effect of protein and
microRNA contents in skeletal muscle-derived EVs in various cancers, including
prostate cancer. Here we review current knowledge of the tumor-derived EVs in
prostate cancer progression and metastasis, the role of exercise in skeletal muscle-
derived EVs circulating levels and the alteration of their contents, and the potential tumor-
suppressive effect of skeletal muscle-derived EV contents in prostate cancer. In addition,
we review the proposed mechanism of exercise in the uptake of skeletal muscle-derived
EVs in prostate cancer.
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INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed cancer in 112 countries with over 1.4 million
new cases estimated in 2020, which is 14.1% of all new cancer diagnoses (1). Moreover, 370,000 men
were estimated to die from prostate cancer in 2020 (6.8% of deaths caused by all cancer) (1). Early
detection and advancement in treatments have improved survival for patients with PCa (1).
However, these treatments can also have enduring adverse effects, such as the loss of lean mass and
Frontiers in Oncology | www.frontiersin.org September 2021 | Volume 11 | Article 7460401
Edited by:
Tanya I Stoyanova,
Stanford University, United States
Reviewed by:
Lucas Delmonico,
Federal University of Rio de Janeiro,
Brazil
Avishay Sella,




†These authors have contributed
equally to work and share
first authorship
Specialty section:
This article was submitted to
Genitourinary Oncology,
a section of the journal
Frontiers in Oncology
Received: 23 July 2021
Accepted: 27 August 2021
Published: 14 September 2021
Citation:
Zhang Y, Kim J-S, Wang T-Z,
Newton RU, Galvão DA,
Gardiner RA, Hill MM and Taaffe DR
(2021) Potential Role of Exercise





published: 14 September 2021
doi: 10.3389/fonc.2021.746040
bone mass, fat mass gain, post-surgery incontinence, metabolic
imbalance, and reduced quality of life (2–4).
Exercise or physical activity has been receiving attention in
patient care in the oncology setting (5) due to the increasing body
of research in the field of exercise oncology. Multiple
epidemiological studies (6, 7) and clinical trials (8–10)
consistently report improvements in health-related outcomes
for PCa patients. In addition, preclinical murine model studies
have also demonstrated a reduced PCa tumor volume and
delayed tumor growth with an exercise stimulus (11, 12), and
provide a strong mechanistic case for clinical trials to be tested on
cancer outcomes. However, while numerous hypotheses exist,
the mechanisms by which exercise influences tumor biology are
not fully understood (13).
As such, multiple studies have been conducted to reveal the
mechanisms of exercise-induced benefits for cancer patients.
Alteration in circulating factors, epigenetic modulation, gene
expression modulation, immune function improvement, and
systemic inflammation reduction have been suggested as
potential mechanisms for exercise-induced tumor suppression
(13, 14). For instance, serum levels of myokines, skeletal muscle
secreted cytokines and peptides, are known to be altered with
skeletal muscle stimulation, and multiple preclinical studies have
shown the tumor-suppressive role of myokines with direct
application in different cancer cell lines, including PCa (13).
Although the beneficial role of exercise in reduced disease
progression, increased survival, and patient care is promising,
the mechanisms underlying how exercise-induced physiological
changes provide tumor-suppressive effects are not
clearly understood.
One potential mechanism proposed is the involvement of
extracellular vesicles (EVs) (15, 16), as exercise-induced skeletal
muscle-derived EVs may reduce cancer cell proliferation and
metastasis (17). EVs are small membrane-surrounded structures
released from various cells (18) that transfer bioactive molecules
(including DNA, RNA, and proteins) from donor to acceptor
cells (19). Two main types of EVs are defined based on their
cellular route of release, exosomes and microvesicles or
microparticles (18). The term ‘exosome’ refers to vesicles of the
endosomal system that are released through the fusion of the
multivesicular body delimiting membrane with the plasma
membrane, while ‘microvesicles’ or ‘microparticles’ refer to
vesicles that directly pinch off the cell surface (18).
During exercise, the release of EVs packaging cytokines and
myokines plays a crucial role in the communication between
muscle and other tissues (20). For instance, the skeletal muscle-
derived EVs have been shown to increase in response to exercise,
and increased uptake of skeletal muscle-derived EVs in the liver
has been shown in animal models (21). Thus, the potential role of
skeletal muscle-derived EVs in reducing cancer proliferation and
migration by transporting anti-oncogenic proteins and
microRNAs (miRNAs) has been proposed (20). This review
will provide the current evidence for the role of exercise in
skeletal muscle-derived EVs concentration in the circulatory
system, the alteration of EV contents, and the potential role
of exercise-induced skeletal muscle-derived EVs content in PCa.
In addition, we propose a potential mechanism whereby exercise
enhances skeletal muscle-derived EV uptake and delivery in PCa.
EXTRACELLULAR VESICLES IN
PROSTATE CANCER
EV cargoes are considered to be biologically influential in cancer
progression, metastasis, and development of drug resistance (22–
24). Furthermore, particular miRNAs in EV cargoes have been
considered as potential diagnostic, prognostic, and predictive
markers for PCa (24–26) (Figure 1). For instance, miR-107,
miR-130b, miR-141, miR-2110, miR-301a, miR-326, miR-331-
3p, miR-432, miR-484, miR-574-3p, and miR-625 were shown to
be substantially increased in circulating EVs from prostate
cancer patients (n=78) compared to healthy individuals (n=28)
(P<0.05) (27). Out of 11 miRNAs shown to increase in prostate
cancer patients, miR-141 and miR-375 were significantly
increased in patients with metastatic prostate cancer (n=16)
compared to patients with localized prostate cancer (n=55)
(P<0.05) (27), suggesting potential of circulating exosomes as
prognostic markers for PCa. Furthermore, exosomal RNA
analysis of plasma from 100 castration-resistant prostate
cancer (CRPC) patients showed significantly shorter overall
survival in patients with higher miR-375 and miR-1290 levels
compared to those with lower miR-375 and miR-1290 levels
(P=0.0045) (28). Although further validation will be required,
this study also showed improved performance of predictive
models for overall survival by incorporating miR-375 and miR-
1290 levels with clinical prognostic factors (time to ADT failure
and PSA level at the time of CRPC diagnosis) (28).
The study by Albino and colleagues (29) investigating the role
of circulating miR-424 positive EVs in PCa patients
demonstrated that metastatic PCa patients (metastatic
castration-sensitive (mCSPC), n=16; metastatic castration-
resistance (mCRPC), n=17) showed a higher frequency
(P<0.05) of circulating miR-424 positive EVs compared to
patients with primary tumors (n=25) and benign prostatic
hyperplasia (BPH, n=6). Moreover, the application of EVs
isolated from plasma of patients (n=17) in the in vitro
environment showed increased tumor-sphere formation in the
application of EVs from patients with mCSPC and mCRPC
compared to primary or BPH patients (P<0.02) (29). In addition,
the level of miR-424 containing EVs was positively associated
with tumor growth in the 3D cell culture environment (tumor-
sphere formation) (P=0.003) (29), suggesting a potential role of
EV-contained miRNAs in PCa progression.
The study by Albino et al. (29) also generated a castration-
resistant cell model using the LNCaP cell line by culturing in an
androgen-depleted condition and showed significantly increased
miR-424 in castration-resistant LNCaP-derived EVs compared
to EVs derived from normal LNCaP cells (P<0.005), confirming
the elevation in circulating miR-424 positive EVs in patients with
advanced PCa (29). Furthermore, the application of EVs isolated
from the castrate-resistant LNCaP-derived EVs to another PCa
cell line, RWPE-1, showed increased tumor formation in a 3D
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cell culture model and cell migration compared to the
application of normal LNCaP cell-derived EVs (P<0.005) (29),
confirming the result by applying human plasma isolated EVs to
cancer cell lines.
Preclinical studies involving PCa cell line-derived EVs and
osteoblast cells also suggest a role for cancer cell-derived EVs in
creating favorable niches for metastasis (30–32). In an in vitro
study investigating the role of prostate cancer cell-induced EVs
in osteoclastogensis and osteoblast proliferation, Inder and
colleagues (30) demonstrated an increase in osteoclastogenesis
of murine RAW264.7 pre-osteoclast cells (37 fold) and human
primary-osteoblast proliferation (1.43 fold) with the presence of
FIGURE 1 | The role of tumor-derived extracellular vesicles in prostate cancer progression and drug resistance. Tumor-derived extracellular vesicles (EVs) transport
the integrins (aV family integrins) to non-aV family integrin presenting cells and promote cell-extracellular matrix communication to promote cancer growth. Tumor-
derived extracellular vesicles also transport oncogenic microRNAs (miRNAs) to recipient cells and promote remodeling of metastatic niches. In addition, drug
resistant prostate cancer cell-derived extracellular vesicles can reduce drug-induced apoptosis in non-drug resistant prostate cancer cells. Moreover, non-drug-
resistant prostate cancer cell-derived extracellular vesicles can increase drug-induced apoptosis in drug-resistant prostate cancer cells.
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EVs isolated from the human prostate cancer cell line PC3
compared with no PC3- induced EVs (P<0.005). However,
secreted soluble factors from PC3 cells were not able to
increase osteoclastogensis of RAW264.7 cells, indicating
requirement for PCa-induced EVs in osteoclastogenesis (30).
Probert and colleagues (31) reported that culture of osteoblast
cells with PC-3 (high metastasis capacity to bone), C4-2
(moderate metastasis capacity to bone), and C4-2-4B (a bone
metastatic lineage of C4-2) PCa cell line-derived EVs resulted in
a significant increase of osteoblast cell viability (P=0.004,
P=0.032, and P=0.001, respectively). In addition, co-culture of
the osteoblast cells preincubated with PCa derived-EVs with PC-
3 and C4-2 cells showed a significant increase (P<0.001) in PCa
cell line viability compared to PCa cell lines co-cultured with
osteoblast cells precultured with non- PCa cell lines (31). This
study also showed a significant increase of PCa abundant
miRNA in osteoblast and induced functional changes of
osteoblast via EVs transported miRNA, suggesting a role of
PCa cell line-derived EVs in generating metastatic niches (31).
Similarly, there is also preclinical evidence for the role of EVs in
transferring integrins to different subsets of PCa cell lines (33, 34).
The integrins are a diverse family of glycoproteins that allows cells
to interact with extracellular matrix (ECM) molecules and, in
cancer, overexpression of the integrins in cancer cells contributes
to migration and invasion by disrupting the ECM molecules (35).
Studies have showed increased integrins (such as aVb6 and aVb3)
in PCa cell lines (PC-3 and RWPE) and PCa cell line-derived
exosomes (33, 34). Incubation of aVb6 negative PCa cell line
(DU145) or non-tumorigenic prostate epithelial cells with PCa cell
line-derived exosomes results in de novo expression of these
integrins in aVb6 negative PCa cell and non-tumorigenic
prostate epithelial cells (33, 34). These results suggest that
tumor-derived EVs can transfer surface proteins, especially
integrins, and enhance migration and invasion of tumor cells.
EVs have also been reported to be involved in PCa drug
resistance (36). Panagopoulos and co-workers (37) showed
increased camptothecin (CPT, chemotherapy drug) resistance in
CPT sensitive DU145 cells when EVs isolated from CPT resistant
RC1 PCa cell line conditioned growth media was applied.
However, when RC1 cells were cultured with EVs isolated from
DU145, CPT-induced apoptosis was increased in the RC1 cells. In
addition, when PCa cell lines DU-145 and 22Rv1 cells were
cultured with the presence of EVs isolated from docetaxel
resistance, PCa cell lines demonstrated docetaxel resistance (38).
Furthermore, application of exosomes isolated from docetaxel
responding PCa patients (n=6) and non-responding PCa
patients (n=2) to the DU145 PCa cell line showed increased
docetaxel-resistance in DU145 cells cultured with exosomes
isolated from docetaxel non-responders, suggesting the potential
role of tumor-cell derived EVs in drug resistance (38).
EXERCISE AND PROSTATE CANCER
Multiple epidemiological studies in clinical oncology have
consistently reported the positive impact of exercise in
reducing PCa progression and enhancing survival. For
instance, Kenfield and co-workers reported a 61% reduced risk
(P=0.03) of PCa-related death (6) while Richman and co-
workers reported a 57% reduction in disease progression
(P=0.03) (7) in those with higher physical activity levels (≥3
hours/week) compared to those with lower physical activity
levels. Furthermore, in preclinical studies, direct application of
human serum obtained after exercise from healthy individuals to
PCa cell line LNCaP showed a significant reduction in LNCaP
cell growth (12). In addition, reduced tumor volume and delayed
tumor growth was evident in a murine model injected with
LNCaP cells exposed to human serum obtained after a bout of
exercise compared with cells exposed to human serum acquired
before exercise, suggesting a potential role for exercise in
reducing tumor progression in vivo (12). Similar results were
shown in the report by Hwang et al. (11), where human serum
obtained after exercise from healthy older individuals (age > 60)
was directly applied to PC-3 PCa cell lines. In addition, exercise
increased blood delivery at the tumor site in a PCa animal model
(R-3327 MatLyLu tumor cell orthotopically injected mice model)
and reduced aggressiveness of PCa cells via reduced hypoxia
at the tumor site (39) suggesting that exercise-induced
physiological changes might have positive effects on
cancer progression.
In addition, increased lean mass in PCa patients might also
positively impact patient outcomes (10). In our recent systemic
review and meta-analysis of the efficacy of exercise in improving
supportive care outcomes in PCa patients with a range of
treatments, improvements (P<0.001) in whole-body fat mass
(-0.6 kg), lean mass (+0.5 kg), and appendicular lean mass (+0.4
kg) after exercise compared to usual care were noted (9).
Furthermore, in our randomized controlled trial involving 57
PCa patients undergoing androgen deprivation therapy (ADT), 3
months of exercise significantly increased muscle strength,
physical function, lean mass, and a number of patient-reported
outcomes (8). Moreover, a recent retrospective report also
showed that men with PCa exhibited increased prostate-
specific antigen (PSA) progression-free survival and
radiological progression-free survival in those with higher lean
mass (P=0.03 and P<0.001, respectively) (10), providing a strong
case for PCa patients to engage in exercise, especially of an
anabolic nature to enhance or preserve lean mass.
SKELETAL MUSCLE DERIVED EVS
DURING EXERCISE AND PROSTATE
CANCER
Over the past decade, skeletal muscle has been identified as an
important secretory organ producing a range of cytokines and
peptides called myokines (40). In addition, in response to exercise
training, skeletal muscle releases miRNAs into the circulation
(41), and miRNAs, messenger RNAs (mRNAs), DNA, piwi-
interacting RNAs (piRNAs), transfer RNAs (tRNAs), and
myokines loaded into EVs for intercellular communication (20,
21). Moreover, clinical and preclinical studies have shown
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alteration of skeletal muscle-derived EVs concentration in the
circulatory system and their contained protein levels are also
altered by exercise (21, 42–48) (Table 1 and Figure 2).
Effect of an Exercise Bout on Skeletal
Muscle-Derived EVs
Emerging clinical exercise trials are building our understanding of
the effect of exercise bouts on exercise-derived EVs in both human
and animal models (Table 1 and Figure 2). Frühbeis and colleagues
(44) showed that the level of small EVs of 100-130 nm that carry
proteins characteristic of exosomes in plasma increased by an
average of 5.2 times (Flot1, P=0.0021; Hsp/Hsc70, P=0.0021) in
12 healthy individuals in response to cycling or running until
exhaustion. Similarly, another acute exhaustive exercise trial
involving 16 healthy subjects also demonstrated a significant
increase of EVs in serum at the peak exercise workload
compared to at rest (P<0.05) (42), indicating an effect of
exhaustive exercise in increasing circulating EVs concentration.
Elevation of serum EV concentrations and protein contents
have also been shown after moderate-intensity aerobic exercise.
Nielsen and colleagues demonstrated elevation of CD36+ and
FATP4+ skeletal muscle-derived EVs in serum after 60 minutes
of moderate-intensity aerobic exercise (70% VO2max) in both
healthy (n=14; CD36+, 52%, P=0.019) and patients with
metabolic disease (n=13; CD36+, 55%, P=0.016; FATP4+, 53%,
P=0.007) compared to at rest (46). Moreover, Rigamonti and
colleagues (48) showed a significant elevation of skeletal muscle-
derived EVs (sarcoglycan-a+EVs) in serum obtained
immediately after 30 minutes of aerobic exercise (60%
VO2max) compared to at rest (P=0.016), whereas monocyte/
macrophage (CD14+EVs), endothelium (CD62E+EVs), and
adipose tissue (FABP+EVs) derived EVs were unchanged. In
addition, a study investigating the effect of 60 minutes of cycling
exercise on circulating small vesicle concentrations and contents
in 11 healthy subjects showed elevated circulating small vesicle
levels with a significant alteration of 322 proteins after the
exercise bout compared to pre-exercise (21).
Not only moderate-intensity aerobic exercise but high and
low-intensity exercise also have been shown to increase serum
EVs concentration and EVs protein content (45, 47). A clinical
study involving a 40-minute bout of vigorous-intensity aerobic
exercise (80%VO2 max) in 22 healthy subjects reported the
presence of skeletal muscle-derived EVs (sarcoglycan-a+EV) in
a cytofluorimetric analysis and level of muscle-specific mRNAs,
TABLE 1 | Effect of exercise on circulating extracellular vesicle concentration and contents.
Ref. Subject Subject number Exercise protocol Results
Frühbeis et al. (44) Healthy
human (male)
Cycling; n=8 Incremental cycling (increase power by
50 W every 3-min until exhaustion)
Cycling: 2.7 fold ↑ in small EVs; Flot1, Hsp/Hsc70, Tsg101
↑ (average 5.2 fold)
Treadmill; n=4 Incremental treadmill (increase speed by
2 km/h every 3-min until exhaustion)
Treadmill: 1.5 fold ↑ in small EVs; significant ↑ Flot 1
Oliveira et al. (47) Rats Non-ex; n=4 Acute aerobic exercise Serum EVs concentration ↑ (non-ex, 1.1x109 unit/ml; low-
ex, 3x109 unit/ml; mod-ex, 2.5x109 unit/ml; high-ex,
3.0x109 unit/ml); EVs protein concentration ↑ (non-ex,
0.935 mg/ml; low-ex, 4.33 mg/ml; mod-ex, 4.31 mg/ml;
high-ex, 4.31 mg/ml); rno-miR330-5p, 10b-5p, 142-3p,
and 410-3p ↑in exercise-EVs
Low-ex; n=5 (40 min)
Mod-ex; n=4 Low-ex: 14-16 m/min
High-ex; n=5 Mod-ex: 20-22 m/min
High-ex: 24-26 m/min
Bei et al. (42) Human, Human; n=16 Human: acute exercise stress test till
exhaustion
Human: EVs ↑ at peak exercise compared to rest
Mice Mice; n=4 Mice: 5-90 min swimming, 2 day/week
for 3 weeks
Mice: 1.85-fold increase after 3-week swimming exercise
Bertoldi et al. (43) Rat 3-m-old; n=12 (ex=6,
con=6)
Daily 20 min treadmill running for
2 weeks
CD36 (exosome marker) ↑ after 18 hours following exercise





Nielsen et al. (46) Healthy human,
T2DM patients
Healthy subjects; n=14 Acute aerobic exercise (60min) 70%
VO2max
Healthy subjects: 52%↑CD36+ SkM-EVs after exercise
T2DM patients; n=13 T2DM patients: 55% ↑CD36+ SkM-EVs after exercise
53% ↑FATP4+SkM-EVs after exercise
Rigamonti et al. (48) Obese human,
Healthy human
Obese subject; n=15 Acute moderate constant workload
exercise (30 min) 60% VO2max
SCGA+EVs ↑ immediately after exercise, CD14+EVs ↔,
CD62+EVs ↔, FABP+EVs ↔
Healthy subject; n=8
Whitham et al. (21) Healthy human n=22 Acute cycling until exhaustion (~60 min) Circulating small vesicle levels ↑ immediately after exercise,
322 EV protein contents altered30 min at 55% VO2max, 20 min at 70%
VO2max, ~10 min (until exhaustion) at
80% VO2max
EV, Extracellular vesicle; Non-ex, non-exercise group; Low-ex, low-intensity exercise group; Mod-ex, moderate-intensity exercise group; High-ex, high-intensity exercise group; T2DM,
type II diabetes; SkM-EVs, skeletal muscle-derived extracellular vesicle; FATP4, long-chain fatty acid transport protein 4; SCGA, sarcoglycan-a; FABP, fatty acid binding protein. ↑ indicate
significant increase (p<0.05); ↔ indicate no change.
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such as miR-181a-5p and mi-133b, in sarcoglycan-a+EVs to be
significantly increased after exercise (P<0.05) (45). Furthermore,
in a preclinical study, 18 mice were divided into 4 groups, non-
exercise, low-intensity exercise, moderate-intensity exercise, and
high-intensity exercise, and undertook 40 minutes of treadmill
exercise at a speed of 14-16 m/min (20% below maximum lactate
steady state (MLSS), 20-22 m/min (at MLSS), and 24-26 m/min
(20% above MLSS) (47). Although there were no significant
differences among exercise groups in serum EVs concentration, a
significant difference in EVs concentration was shown in all
exercise groups compared to the non-exercise group (low-ex vs.
non-ex, P=0.014; mod-ex vs. non-ex, P=0.021; high-ex vs. non-
ex, P=0.02) (47), whereas the size of EVs in the exercise groups
was not changed compared to the non-exercise group. Similarly,
EV protein concentrations were also significantly increased in all
exercise groups compared to the non-exercise group (P=0.014)
(47). In addition, 12 miRNAs in serum EVs (rno-miR-128-3p,
1033p, 330-5p, 148a-3p, 191a-5p, 10b-5p, 93-5p, 25-3p, 142-5p,
3068-3p, 142-3p, and 410-3p), predicted to target genes involved
in the MAPK signal transduction pathway, were found to be
differentially expressed after exercise in the animal model (47).
These results suggest that low- and high-intensity exercise may
also increase EV concentrations and protein content levels.
Effect of Chronic Exercise Training on
Skeletal Muscle-Derived EVs
Due to the lack of clinical studies investigating the effect of
chronic exercise training on circulating EVs concentration,
insight into the effect of exercise training on resting circulating
EVs concentration can only be derived from animal studies.
However, positive associations between aerobic capacity
(VO2max) and EVs containing miRNAs (miR-1, R=0.58,
P=0.01; miR-133b, R=0.54, P=0.02; miR-181a-5p, R=0.63,
P=0.006; miR-206, R=0.5, P=0.003; miR-499, R=0.54, P=0.02)
were found in the study by Guescini and colleagues (45)
involving 18 healthy subjects suggesting that improvements in
aerobic capacity due to chronic exercise might have a role in
altering EV contents. Furthermore, a study by Bei and co-
workers showed a 1.85-fold increase of circulating EVs after 3
weeks of swimming exercise in a mice model (42), and Bertoldi
and colleagues demonstrated elevation of CD36 (exosome
marker) in serum after 2 weeks of daily moderate-intensity
exercise in a rat model at different ages (43). Although these
studies suggest the elevation of circulating EVs concentration,
the exercise period was short, and substantial exercise adaptation
may not have occurred in the animals. Longer duration studies
for exercise adaptation and investigation of the origin of these EV
FIGURE 2 | Effect of exercise on extracellular vesicles. Exercise may increase the secretion of extracellular vesicles (EVs) into the circulatory system and alter the
concentration of proteins and microRNAs (miRNAs) in skeletal muscle-derived extracellular vesicles. MicroRNAs in skeletal muscle-derived extracellular vesicles may
induce epigenetic regulation in prostate cancer cells and reduce cell progression, transformation, and invasion. In addition, skeletal muscle-derived extracellular
vesicles containing proteins, including myokines, have a direct tumor-suppressive effect.
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responses to chronic training are required to enhance our
understanding of the effect of chronic exercise on circulating
skeletal muscle-derived EV resting concentrations.
Potential Role of Skeletal Muscle-Derived
EV Cargoes in Prostate Cancer
Exercise can modify the biology of PCa via its effects on muscle
hypertrophy, adipose tissue oxidation, increased insulin
sensitivity, increased osteogenesis, reduced inflammation, and
increased antitumor activity (49). Among the physiological
alterations induced by exercise, the tumor-suppressive role of
skeletal muscle secreted proteins (myokines) and miRNAs in
PCa suggests a regulatory role of skeletal muscle-derived EV-
containing proteins in PCa (Figure 2).
Myokines, such as IL-6, irisin/FNDC5, decorin, oncostatin M
(OSM), and secreted protein acidic and rich in cysteine (SPARC),
have shown the potential of a direct tumor-suppressive effect in
different cancer cell lines, including PCa (13). For example, in vitro
administration of IL-6 resulted in a reduction of hormone-sensitive
PCa cell line proliferation by reducing androgen receptor
expression (50), and application of irisin to PCa cell lines
significantly reduced cell viability (P<0.05) (51). Moreover, direct
application of SPARC and decorin significantly reduced PCa cell
line growth by reduced Cyclin D1 and epidermal growth factor
receptor (EGFR) activation, respectively (52, 53). Levels of
myokines have also been shown to be altered in intercellular
muscle protein and mRNA levels (13), supporting the analytic
results of protein contents in skeletal muscle-derived EV contents
by Whitham and co-workers, which showed alteration of protein
contents in skeletal muscle-derived EVs (21).
The importance of epigenetics (including DNA methylation,
histone modification, and miRNA and long non-coding RNA
(lncRNA) regulation) in cellular transformation, tissue invasion,
induction of angiogenesis, escape from immune surveillance, and
metastasis is increasingly being recognized in cancer
development and progression. In the pathogenesis of human
PCa, somatic epigenetic alterations appear earlier than genetic
changes, as well as more commonly and more consistently (54).
Recent research has implicated EVs in epigenetic regulation of
the cancer microenvironment to affect cancer progression (55).
Bioinformatic analysis has indicated that many mRNAs and
proteins contained in EVs are involved in epigenetic modulation
(56). Proteins, mRNAs, microRNAs, and non-coding RNAs in
EVs alter the phenotype of target cells by transferring mRNA, a
transcriptional modulator, or degrading mRNA rapidly (57).
Recently, it has been shown that aerobic exercise is a potential
epigenetic modifier. Aerobic exercise induces epigenetic changes
through several mechanisms, including chromatin methylation,
histone acetylation, DNA methylation, and miR expression.
MiRs secreted into the extracellular microenvironment via EVs
may play an important role in epigenetic modulation (58).
Uptake of Skeletal Muscle-Derived EVs by
Prostate Cancer Cells: Potential Myokine
Involvement
Uptake of EVs by targeted cells is an important process to elicit
the functional effects by initiating signaling events at the surface
of recipient cells or transferring EV contents into recipient cells
(59). Although the uptake of EVs by recipient cells is a critical
process in cell-to-cell or ECM-to-cell communication via EVs,
this process is poorly understood because the uptake of EVs
depends on the specific properties of the recipient cells (60).
However, the potential role of skeletal muscle-induced myokines,
especially irisin, in skeletal muscle-derived EVs and cancer cell
communication has been proposed in a recent review by
Darkwah et al. (17) (Figure 3).
Fibronectin type III domain containing 5 (FNDC5), a type1
transmembrane glycoprotein embedded in the skeletal muscle
cell membrane, is a precursor of irisin and with exercise stimulus
not only does FNDC5 expression increase on the membrane of
skeletal muscle cells but the fibronectin III domain is cleaved and
released to the extracellular site as irisin (61, 62). Irisin has been
shown to increase energy expenditure by inducing white
adipocyte browning and helps to maintain metabolic
homeostasis, reducing body weight, improving glucose
metabolism, and improving insulin sensitivity (62–64).
Furthermore, various preclinical studies have demonstrated a
direct reduction of growth of various cancer cell lines after
applying exogenous irisin including PCa (13).
The receptors of irisin were not identified until recently.
However, irisin has been shown to have a high affinity to
specific integrin families, aV family, in bone and fat cells (65).
Furthermore, previous studies have demonstrated high aV
family integrins (such as aVb6 and aVb3) expression in PCa
cell lines, and these transmembrane proteins can be transferred
to other recipient cells (33, 34), suggesting the potential role of
irisin in increasing skeletal muscle-derived EVs and PCa cell
communication. Although there is no research investigating the
expression of FNDC5 in the membrane of skeletal muscle-
derived EVs, the process of microvesicle biogenesis suggests
the surface protein of the cell might be transferred to EVs (17).
Taken together, it could be proposed that irisin-aV family
integrins interaction can directly induce a tumor-suppressive
effect on PCa cells and possibly increase skeletal muscle-derived
EVs-PCa cell communication through an extracellular domain of
FNDC5 (irisin)-integrin interaction. This may increase the
internalization of skeletal muscle-derived EVs into PCa cells to
elicit the functional role of EV contents in PCa (17).
Furthermore, circulating irisin may also interact with PCa cell-
derived EV containing integrins and interfere with the delivery of
PCa cell-derived EVs to the cells near PCa cells and contribute to
remodeling the pre-metastatic environment (17). However,
further investigation examining the role of irisin-integrin
interaction in PCa is required to fully elucidate skeletal
muscle-derived EVs uptake in PCa and involvement
of myokines.
DISCUSSION
The importance of exercise oncology, the application of exercise
medicine in cancer, has been well recognized in clinical oncology
(5). Epidemiological (6, 7, 10) and clinical (8, 9) studies
examining the effect of exercise in PCa patients have further
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established the role of exercise in patient care for men with PCa.
Moreover, exercise-induced circulating factor alteration,
epigenetic modulation, and gene expression have been
suggested as potential mechanisms whereby exercise may
impact disease progression in men with PCa (13, 14).
Recently, extracellular vesicles have been highlighted in cell-
to-cell and cell-to-extracellular matrix communications, and in
PCa tumor-derived EVs have been suggested as a therapeutic
target (24–26). Tumor-derived EVs have potential in delivering
oncogenic proteins, surface proteins, and miRNAs to non-tumor
cells and contribute to progression of PCa by initiating growth-
promoting signal cascades or creating metastatic niches among
non-tumoral cells near cancerous cells (29, 31, 33, 34). As such,
multiple proteins, miRNAs, and surface proteins in tumor-
derived EVs have been identified as potential predictable
markers for PCa progression (22, 23, 26). However, a few
clinical exercise trials demonstrating elevation of skeletal
muscle-induced EVs after exercise and preclinical studies
demonstrating a potential tumor-suppressive effect of skeletal
muscle-derived factors (such as myokines and miRNAs) suggest
EVs as a potential delivery mechanism for skeletal muscle
induced proteins and miRNAs in PCa (13, 21, 42–48, 58).
Furthermore, the potential role of myokines in the facilitation
of skeletal muscle-derived EV uptake in cancer has been recently
proposed in a review article by Darkwah and co-workers (17).
It is important to note that research into skeletal muscle-
derived EVs in cancer is at an early stage; more research is
required to fully elucidate the role of exercise in PCa. For
instance, the clinical exercise trials investigating the alteration
of skeletal muscle-derived EVs after exercise are limited to
healthy populations, limiting the generalizability of these
outcomes to cancer patients. Moreover, as common adverse
effects of ADT, a widspread treatment in men with PCa, are a
significant loss of skeletal muscle mass and gain of fat mass (4),
physiology of skeletal muscle biogenesis may differ from that of
healthy subjects (13). The lack of preclinical studies investigating
the direct effect of skeletal muscle-derived EVs on PCa cells also
prevents a clear understanding of the role of exercise-induced
skeletal muscle-derived EVs. Although skeletal muscle
secretomes, such as myokines and miRNAs, have been shown
FIGURE 3 | Potential role of exercise-induced myokines in extracellular uptake in prostate cancer cells. Irisin has a high affinity to aV family integrins, which is highly
expressed in prostate cancer. FNDC5 is a precursor of irisin and with exercise stimulation FNDC5 is increased on the membrane, as is the secretion of irisin from
skeletal muscle. Free irisin and skeletal muscle-derived extracellular vesicles (EVs) containing FNDC5 may travel to the prostate cancer site through the circulatory
system. The high affinity of free irisin to aV family integrins on the prostate cancer cell may directly induce irisin-integrin interaction to elicit the direct tumor-
suppressive effect. Moreover, free irisin may also interact with aV family integrins on tumor-derived extracellular vesicles to interfere with the remodeling of metastatic
niches. Lastly, the irisin domain of FNDC5 on the membrane of skeletal muscle-derived extracellular vesicles may increase internalization of skeletal muscle-derived
extracellular vesicles to prostate cancer cells through FNDC5 (irisin domain)- aV family integrin interaction.
Zhang et al. Exercise-Induced EVs in Prostate Cancer
Frontiers in Oncology | www.frontiersin.org September 2021 | Volume 11 | Article 7460408
to have potential in suppressing tumor growth (13, 49), the direct
communication between skeletal muscle cells and PCa cells via
EVs is yet to be reported.
CONCLUSIONS
Exercise-derived EVs have received increased attention as they
provide an opportunity to understand the mechanistic benefit of
exercise in cancer patients. Emerging evidence indicates that
aerobic exercise affects circulating EV dynamics, including the
size, morphology, and composition. Proteins, miRNAs, mRNAs,
and DNAs packed in exercise-specific EVs may potentially play a
role in preventing PCa development and disease progression.
This review has summarized the preliminary evidence for an
effect of exercise on circulatory levels of skeletal muscle-derived
EV secretion, EV-containing protein or miRNA contents and the
role of EV-containing factors in PCa progression, as well as the
potential involvement of myokines in EV uptake in PCa. Given
the speculative nature of the role of exercise-derived EVs to date,
in the coming decade research will likely clarify the role of EVs
with a focus on the dynamics of EVs in response to specific
exercise modes and dosages, providing opportunities to enhance
our understanding of the tailoring of exercise prescription on
mediating possible cancer outcomes.
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